SOX11-positive MCL tumors have increased tumor angiogenesis network and PDGFA overexpression. (A) GSEA analysis on expression data sets from leukemic MCL primary tumors (16 SOX11-expressing and 22 SOX11-negative (GSE36000)17 showing enriched gene sets related to angiogenesis pathways. NES, P-val, and FDR are shown. Statistical significance is considered when FDR < 0.2. (B) Left panel, Histological sections from representative SOX11-expresing (n = 8) and SOX11-negative (n = 9) splenic MCL primary tumors stained with specific antibodies against human SOX11 (×40) and CD34 (×20). Right panel, Graph showing quantification of number of CD34-positive vessels and percentage of CD34-positive MVD areas of the splenic MCL primary tumors. Bar plot represents the mean percentage ± SD. P-val are shown. The significance of difference was determined by independent samples t test. (C) Representative histological sections from SOX11-positive and SOX11-negative tumors from splenic MCL primary samples (n = 8 and n = 9, respectively) and MCL xenograft tumors (n = 3 and n = 10, respectively) stained with a specific antibody anti-human SOX11 (×40) and PDGFA (×40).
